Market News

South State (SSB) Analysts See $1.19 EPS; Endologix (ELGX) Has 1.07 Sentiment

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $383.05 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

Analysts expect South State Corporation (NASDAQ:SSB) to report $1.19 EPS on January, 26.They anticipate $0.04 EPS change or 3.48% from last quarter’s $1.15 EPS. SSB’s profit would be $43.43M giving it 19.20 P/E if the $1.19 EPS is correct. After having $1.22 EPS previously, South State Corporation’s analysts see -2.46% EPS growth. The stock increased 0.11% or $0.1 during the last trading session, reaching $91.4. About 140,379 shares traded. South State Corporation (NASDAQ:SSB) has risen 19.60% since January 14, 2017 and is uptrending. It has outperformed by 2.90% the S&P500.

South State Corporation operates as the bank holding firm for South State Bank that provides a range of retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans. The company has market cap of $3.34 billion. It accepts demand deposits, savings deposits, interest-bearing demand deposits, certificates of deposit, and other time deposits; and offers lending and credit card, ATM processing, and wealth management and trust services. It has a 23.47 P/E ratio. The firm also provides investment advisory and broker dealer services.

Among 8 analysts covering South State Corp (NASDAQ:SSB), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. South State Corp had 22 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Keefe Bruyette & Woods on Thursday, December 21 with “Buy”. The firm earned “Buy” rating on Tuesday, October 3 by Keefe Bruyette & Woods. Brean Capital maintained the shares of SSB in report on Monday, October 23 with “Hold” rating. The stock of South State Corporation (NASDAQ:SSB) earned “Buy” rating by SunTrust on Monday, January 8. Brean Capital maintained South State Corporation (NASDAQ:SSB) on Wednesday, August 2 with “Hold” rating. Brean Capital maintained the shares of SSB in report on Tuesday, January 2 with “Hold” rating. SunTrust maintained South State Corporation (NASDAQ:SSB) rating on Tuesday, November 28. SunTrust has “Buy” rating and $107.0 target. The firm has “Neutral” rating given on Thursday, October 5 by PiperJaffray. Piper Jaffray maintained the stock with “Hold” rating in Thursday, October 26 report. The rating was maintained by SunTrust on Thursday, October 26 with “Buy”.

The stock decreased 0.65% or $0.03 during the last trading session, reaching $4.59. About 565,964 shares traded. Endologix, Inc. (ELGX) has declined 63.00% since January 14, 2017 and is downtrending. It has underperformed by 79.70% the S&P500.

Ratings analysis reveals 0 of Endologix’s analysts are positive. Out of 3 Wall Street analysts rating Endologix, 0 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. ELGX was included in 3 notes of analysts from September 6, 2016. The firm has “Mkt Perform” rating by Leerink Swann given on Tuesday, September 6. Canaccord Genuity downgraded Endologix, Inc. (NASDAQ:ELGX) rating on Thursday, November 17. Canaccord Genuity has “Hold” rating and $7.5 target. JP Morgan downgraded Endologix, Inc. (NASDAQ:ELGX) on Wednesday, November 16 to “Neutral” rating.

Analysts await Endologix, Inc. (NASDAQ:ELGX) to report earnings on February, 28. They expect $-0.22 earnings per share, 0.00% or $0.00 from last year’s $-0.22 per share. After $-0.11 actual earnings per share reported by Endologix, Inc. for the previous quarter, Wall Street now forecasts 100.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *